NEWPORT BEACH, Calif., Sept. 14, 2026 /PRNewswire/ -- Aviation Capital Group LLC ("ACG"), a premier global full-service aircraft asset manager, today announced the appointment of Jilinda Crowley as Executive Vice President and Chief Financial Officer.

Based at ACG's headquarters in Newport Beach, Ms. Crowley will oversee the Company's financial strategy and lead its Finance team across Treasury, Risk, Tax, Accounting, Pricing, and Financial Planning & Analysis.

Ms. Crowley brings more than 20 years of aviation and aerospace finance experience to ACG. She spent 14 years in senior finance roles at Rolls-Royce before moving from a global aerospace leader into CFO roles with emerging aviation and aerospace businesses, including Electra Aero, magniX and Skydweller Aero.

"We are delighted to welcome Jilinda to our executive team. She brings a wealth of strategic financial leadership experience, as well as a broad perspective gained from across the aviation and aerospace industry. Her experience working with some of the sector's most innovative businesses will bring an additional perspective at an important point in our growth journey, as we position the Company to capitalize on the opportunities ahead," said Thomas Baker, Chief Executive Officer and President of ACG.

Ms. Crowley succeeds Jaime Crear, who has served as interim Chief Financial Officer alongside her role as Chief Administrative Officer. Ms. Crear will continue in her role as Chief Administrative Officer.

About Aviation Capital Group

Aviation Capital Group is one of the world's premier full-service aircraft asset managers with approximately 500 owned, managed and committed aircraft as of June 30, 2026, leased to roughly 85 airlines in approximately 50 countries. It specializes in commercial aircraft leasing and provides certain aircraft asset management services and aircraft financing solutions for third parties. It was founded in 1989 and is a wholly owned subsidiary of Tokyo Century Corporation. Follow ACG on LinkedIn, and for more information, visit www.aviationcapitalgroup.com.

Contact

Media Relations:

[email protected] 

Investor Relations:

[email protected] 

SOURCE Aviation Capital Group

Share this article

CHICAGO, Sept. 14, 2026 /PRNewswire/ -- Health Care Service Corporation (HCSC) has completed the rebranding of its acquired Medicare Supplement and Supplemental Health & Life (SHL) products to HealthSpring. As the second largest Medicare Supplement carrier in the country based on policyholders served, HCSC offers Medicare Supplement plans in 48 states and the District of Columbia.

Medicare Supplement plans, also known as Medigap plans, help cover gaps in Original Medicare, including deductibles, coinsurance and copayments. These plans can help Medicare beneficiaries manage out-of-pocket health care expenses and maintain more predictable costs.

HealthSpring offers SHL products in 49 markets plus the District of Columbia. Supplemental Health & Life products, including Hospital Indemnity and Dental, Vision and Hearing coverage, provide additional financial protection alongside traditional coverage or a Medicare Advantage plan.

Last year, HCSC moved all of its acquired Medicare Advantage and Prescription Drug Plans to the HealthSpring brand.

"We're pleased to cross another exciting milestone in the evolution of our HealthSpring brand," said Jane Funk, vice president of Medicare market growth for HealthSpring. "Wherever members and providers see HealthSpring, they can be confident that they are dealing with a trusted partner that shares their commitment to health and wellness."

For more information about HealthSpring Medicare Advantage, Medicare Prescription Drug Plans, Medicare Supplement (Medigap) and supplemental coverage options available in your area, go to https://HealthSpringMedicare.com/LearnMore.

HealthSpring products and services are provided exclusively by or through operating subsidiaries of Health Care Service Corporation, a Mutual Legal Reserve Company.

About Health Care Service Corporation

Health Care Service Corporation, a Mutual Legal Reserve Company, is the country's largest customer-owned health insurer, serving more than 26 million people across the United States. HCSC provides coverage options for employers large and small, individuals and families, and Medicare and Medicaid plans. HCSC also offers related health care products and services such as pharmacy solutions, life and dental insurance, and health technology through a network of affiliates and subsidiaries.

About HealthSpring

HealthSpring is a national Medicare brand from Health Care Service Corporation, which is the nation's largest customer-owned health insurer. HealthSpring serves more than three million members and offers a range of Medicare coverage options including Medicare Advantage, Medicare Prescription Drug, Medicare Supplement, and Supplemental Health & Life products. As part of the HCSC family of companies, HealthSpring is committed to helping members access quality care, make informed health care decisions and achieve their health and wellness goals. HealthSpring is part of Health Care Service Corporation, a Mutual Legal Reserve Company.

SOURCE HealthSpring

Share this article

New campaign spotlights what patients want from healthcare: an easier way to get an appointment with a doctor who's right for them

NEW YORK, Sept. 14, 2026 /PRNewswire/ -- Zocdoc, the healthcare access infrastructure that connects patients to great care, today launched "Ready to be Seen?", a new integrated marketing campaign about what it really means for patients to both get seen and feel seen.

Too often, patients struggle to find and access care that fits them and their lives. Getting in front of a doctor can mean navigating scheduling hassles, insurance confusion and long waits. In fact, according to a recent Zocdoc survey, 42% of patients say finding and booking a doctor feels like finding a needle in a haystack, and 48% say they dread it.

But getting an appointment is only the first hurdle. Getting an appointment with the right provider is equally important: 71% say finding the right doctor matters as much as getting an appointment quickly. And while 1 in 2 patients (50%) say they wish healthcare providers took more time to understand them, the benefit of finding the right provider is immense: 71% say they are more likely to be honest with a doctor when they feel understood.

"Ready to be Seen?" brings to life how Zocdoc supports patients with both challenges. Zocdoc helps patients find in-network doctors with near-term availability and book instantly. And through verified patient reviews and detailed provider information, patients can choose a doctor who fits their needs — so they don't have to compromise between getting seen and feeling seen.

"Patients shouldn't have to work this hard or compromise this much to get great care," said Brian Irving, Chief Marketing Officer at Zocdoc. "Finding the right doctor who can see you when you're ready is a seemingly simple task that is in fact daunting for most Americans. But we know there are amazing doctors out there, and we've built the way for patients to easily and confidently find them. That's what 'Ready to Be Seen?' is about: making it easier to get through the door, and giving patients the ability and information to find a doctor who truly makes them feel seen."

Developed with creative agency SpecialGuest, "Ready to be Seen?" reinvents one of healthcare's most familiar phrases through that double meaning. The campaign brings it to life through hyper-specific patient truths, from a runner looking for a podiatrist who understands he isn't giving up marathon training to a patient looking for an allergist who accepts that both their girlfriend and her cat are a "package deal".

"A patient's need for care is one of the most personal things in their lives. They bring their fears, priorities, quirks and non-negotiables with them," said Aaron Duffy, co-founder and CCO of SpecialGuest. "Patients want to feel seen. Zocdoc helps people more easily find and book a doctor who really gets them, and we wanted the work to celebrate just how personal and achievable finding the right fit can be."

The campaign launches September 14 and rolls out over several months across TV, audio, social, and digital, with out-of-home creative in New York City and Houston.

About Zocdoc

Zocdoc is the healthcare access infrastructure that connects patients to great care. By powering access to care everywhere patients search, Zocdoc helps them move from being stuck to being seen. Each month, millions of patients find and book appointments with providers, powered by Zocdoc—on the company's website and app, and across AI platforms, online search, insurance directories, providers' websites, practice phone lines, and more—with the typical appointment happening within 24 to 72 hours from booking.

With nearly two decades of experience unifying healthcare's fragmentation, Zocdoc is uniquely positioned to power access across insurance plans, PMS and EHR systems, specialties, visit types, and provider organizations of every size. By fixing healthcare at the start, Zocdoc empowers patients to get the care they need, when they need it, while helping providers be bookable everywhere patients search.

SOURCE Zocdoc

Share this article

Designation is driven by compelling Phase 2 clinical data in patients with complicated Staphylococcus aureus bacteremia showing AP-SA02 may offer substantial improvement over available therapies

Potentially accelerating the path to market for this innovative antibacterial treatment

AP-SA02 now holds Breakthrough Therapy, Fast Track and QIDP designations, providing strong regulatory validation

LOS ANGELES, Sept. 14, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity and potency, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that the U.S. Food and Drug Administration (the "FDA") has granted Breakthrough Therapy designation to AP-SA02, the Company's intravenously administered Staphylococcus aureus ("S. aureus") multi-phage product candidate, for adjunct treatment of complicated bacteremia caused by methicillin-sensitive S. aureus ("MSSA") or methicillin-resistant S. aureus ("MRSA"). Breakthrough Therapy designation is intended to expedite the review of medicines that treat a serious or life-threatening condition and have shown preliminary clinical evidence indicating the potential for substantial improvement over available therapies.

"The decision by the FDA to grant Breakthrough Therapy designation to AP-SA02, in addition to Qualified Infectious Disease Product ("QIDP") and Fast Track designations, recognizes the urgent need for new treatment options for patients with complicated S. aureus bacteremia ("SAB"), including MRSA, where many outcomes remain poor despite current standard-of-care," said Dr. Deborah Birx, Chief Executive Officer of Armata. "Based on the Phase 2 clinical trial data, we believe AP-SA02 has the potential to represent an important advancement in the treatment of complicated SAB, a serious bloodstream infection that continues to be associated with significant relapse rate, morbidity and mortality. If ultimately confirmed in Phase 3 and approved, AP-SA02 has the potential to become the first antibacterial therapy approved based on superiority to current standard-of-care treatment in this patient population. We are grateful for the FDA's enhanced engagement and are committed to working closely with the Agency to efficiently advance the development and review of AP-SA02, with the goal of bringing this potential new treatment option to patients as quickly as possible."

Critically, the Breakthrough Therapy designation is supported by data from the successful Phase 1b/2a diSArm study in adults with complicated SAB. Armata's proprietary purification process yielded the production of a high-purity, high-titer AP-SA02 drug product formulation enabling repetitive dose intravenous administration every six hours for five days. This dosing regimen was well tolerated with no serious adverse events attributed to AP-SA02, and, when added to best available antibiotic therapy ("BAT") demonstrated higher and earlier clinical cure rates than placebo plus BAT. At the end-of-study assessment, 28 days after completion of BAT, 100% of patients treated with AP-SA02 maintained clinical response without relapse, compared with 75% of patients receiving placebo. Patients treated with AP-SA02 also demonstrated favorable trends across multiple measures of disease resolution, including more rapid normalization of C-reactive protein (CRP) and Interleukin-10 (IL-10), biomarkers associated with mortality risk and complications in SAB.

About Breakthrough Therapy Designation

Breakthrough Therapy designation is a program designed by the FDA to expedite the development and review of therapies that are intended to treat a serious or life-threatening condition where preliminary clinical evidence indicates potential substantial improvement over available therapies on a clinically significant endpoint. A Breakthrough Therapy is eligible for all features of Fast Track designation, in addition to comprehensive, cross-disciplinary collaboration with the FDA to design the most efficient clinical development program, and organizational commitment from senior FDA managers to expedite development and review.

About AP-SA02

Armata is developing AP-SA02, a fixed multi-phage cocktail, for the adjunct treatment of complicated Staphylococcus aureus bacteremia caused by methicillin-sensitive S. aureus (MSSA) or methicillin-resistant S. aureus (MRSA). AP-SA02 has received Qualified Infectious Disease Product (QIDP) designation, Fast Track designation, and Breakthrough Therapy designation from the FDA. The diSArm study (NCT05184764) was a Phase 1b/2a, multicenter, randomized, double-blind, placebo-controlled, multiple ascending dose escalation study of the safety, tolerability, and efficacy of intravenous AP-SA02 in addition to best available antibiotic therapy ("BAT") compared to BAT alone (placebo) for the treatment of adults with complicated S. aureus bacteremia. Positive results from the Phase 2a diSArm study were highlighted in a late-breaking oral presentation at IDWeek 2025™ in October 2025. The Phase 1b/2a clinical development of AP-SA02, and activities related to End-of-Phase 2 and Armata's preparation and readiness for its planned Phase 3 clinical study, is partially supported by a $28.7 million Department of War (DoW) award, received through the Medical Technology Enterprise Consortium (MTEC) and managed by the Naval Medical Research Command (NMRC) – Naval Advanced Medical Development (NAMD) with funding from the Defense Health Agency and Joint Warfighter Medical Research Program. The Company plans to advance AP-SA02 into a Phase 3 superiority study in complicated SAB, anticipated to initiate in the second half of 2026.

About Armata Pharmaceuticals, Inc.

Armata is a late clinical-stage biotechnology company focused on the development of high-purity and potency, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other important pathogens. Armata is committed to advancing phage therapy with drug development expertise that spans bench to clinic including in-house phage-specific current Good Manufacturing Practices ("cGMP") manufacturing to support full commercialization.

Forward Looking Statements

This communication contains "forward-looking" statements as defined by the Private Securities Litigation Reform Act of 1995. These statements relate to future events, results or to Armata's future financial performance and involve known and unknown risks, uncertainties and other factors which may cause Armata's actual results, performance or events to be materially different from any future results, performance or events expressed or implied by the forward-looking statements. In some cases, you can identify these statements by terms such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "will," "would" or the negative of those terms, and similar expressions. These forward-looking statements reflect management's beliefs and views with respect to future events and are based on estimates and assumptions as of the date of this communication and are subject to risks and uncertainties including risks related to Armata's development of bacteriophage-based therapies; Armata's planned clinical trials; ability to staff and maintain its production facilities under fully compliant cGMP; ability to meet anticipated milestones in the development and testing of the relevant product; ability to be a leader in the development of phage-based therapeutics; ability to achieve its vision, including improvements through engineering and success of clinical trials; ability to successfully complete preclinical and clinical development of, and obtain regulatory approval of its product candidates and commercialize any approved products on its expected timeframes or at all; and Armata's estimates regarding anticipated operating losses, capital requirements and needs for additional funds. Additional risks and uncertainties relating to Armata and its business can be found under the caption "Risk Factors" and elsewhere in Armata's filings and reports with the U.S. Securities and Exchange Commission (the "SEC"), including in Armata's Annual Report on Form 10-K, filed with the SEC on March 25, 2026, and in its subsequent filings with the SEC.

Armata expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Armata's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

Media Contacts:

At Armata:

Pierre Kyme

[email protected]

310-665-2928

Investor Relations:

Joyce Allaire

LifeSci Advisors, LLC

[email protected]

212-915-2569

SOURCE Armata Pharmaceuticals, Inc.

Share this article

VANCOUVER, BC, Sept. 14, 2026 /PRNewswire/ -- First Mining Gold Corp. ("First Mining" or the "Company") (TSX: FF) (OTCQX: FFMGF) (FRANKFURT: FMG) is pleased to announce that it has been added to the MVIS® Global Junior Gold Miners Index ("MVGDXJ"), the underlying benchmark index for the VanEck Junior Gold Miners ETF ("GDXJ"). Pursuant to the MVGDXJ's semi-annual review and rebalancing, First Mining's inclusion will be effective at the close of trading on September 18, 2026. The GDXJ is a widely followed gold industry exchange traded fund that provides investors with exposure to a portfolio of the most liquid junior gold and silver mining, development and exploration companies.

"We believe our inclusion in the GDXJ will enhance First Mining's visibility among institutional and retail investors, improve trading liquidity, and increase our exposure to global capital markets as we continue to advance our gold projects in Ontario and Quebec," stated Dan Wilton, CEO of First Mining. "This is an exciting step forward for the Company and our shareholders."

About MVGDXJ

The MVIS® Global Junior Gold Miners Index tracks the performance of the most liquid small-cap companies in the global gold and silver mining industries. This is a modified market cap-weighted index, and only includes companies that generate at least 50% of their revenue from gold or silver mining, or at least 50% of their mining mineral resources are from gold or silver.

About GDXJ

VanEck Junior Gold Miners ETF seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVGDXJ, which is intended to track the overall performance of small-capitalization companies that are involved primarily in the mining for gold and/or silver.

About First Mining Gold Corp.

First Mining is a gold developer advancing two of the largest gold projects in Canada, the Springpole Gold Project in northwestern Ontario, where the federal Environmental Assessment for the Springpole Project was approved in June 2026, and the Duparquet Gold Project in Quebec, a PEA-stage development project located on the Destor-Porcupine Fault Zone in the prolific Abitibi region. First Mining also owns a 20% project interest in the Pickle Crow Gold Project in Ontario and large equity interest in Seva Mining Corp.

First Mining was established in 2015 by Mr. Keith Neumeyer, founder and CEO of First Majestic Silver Corp.

ON BEHALF OF FIRST MINING GOLD CORP.

Daniel W. Wilton

Chief Executive Officer and Director

Cautionary Note Regarding Forward-Looking Statements

This news release includes certain "forward-looking information" and "forward-looking statements" (collectively "forward-looking statements") within the meaning of applicable Canadian and United States securities legislation including the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements are made as of the date of this news release. Forward-looking statements are frequently, but not always, identified by words such as "expects", "anticipates", "believes", "plans", "projects", "intends", "estimates", "envisages", "potential", "possible", "strategy", "goals", "opportunities", "objectives", or variations thereof or stating that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved, or the negative of any of these terms and similar expressions.

Forward-looking statements in this news release relate to future events or future performance and reflect current estimates, predictions, expectations or beliefs regarding future events. All forward-looking statements are based on First Mining's or its consultants' current beliefs as well as various assumptions made by them and information currently available to them. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. Forward-looking statements in this news release include, but are not limited to, statements with respect to: liquidity of the GDXJ; feasibility and permitting activities related to the Springpole Gold Project; realizing the value of the Company's gold projects for the Company's shareholders; Company's business strategy; future planning processes. Statements concerning proven and probable mineral reserves and mineral resource estimates may also be deemed to constitute forward-looking statements to the extent that they involve estimates of the mineralization that will be encountered as and if the property is developed, and in the case of measured and indicated mineral resources or proven and probable mineral reserves, such statements reflect the conclusion based on certain assumptions that the mineral deposit can be economically exploited.

Forward-looking statements reflect the beliefs, opinions and projections of management on the date the statements are made and are based upon a number of assumptions and estimates that, while considered reasonable by the respective parties, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Such factors include, without limitation the Company's business, operations and financial condition potentially being materially adversely affected by the outbreak of epidemics, pandemics or other health crises, and by reactions by government and private actors to such outbreaks; risks to employee health and safety as a result of the outbreak of epidemics, including pandemics or other health crises, that may result in a slowdown or temporary suspension of operations at some or all of the Company's mineral properties as well as its head office; fluctuations in the spot and forward price of gold, silver, base metals or certain other commodities; fluctuations in the currency markets (such as the Canadian dollar versus the U.S. dollar); changes in national and local government, legislation, taxation, controls, regulations and political or economic developments; requirements for additional capital; changes in project parameters as plans continue to be refined; variations in ore reserves, grade or recovery rates; actual performance of plant, equipment or processes relative to specifications and expectations; risks and hazards associated with the business of mineral exploration, development and mining (including environmental hazards, industrial accidents, unusual or unexpected formations, pressures, cave-ins and flooding); effectiveness of environmental mitigations and strategies including production of NAG and PAG tailings and mine rock and water management strategies, the presence of laws and regulations that may impose restrictions on mining; employee relations; relationships with and claims by local communities, indigenous populations and other stakeholders; availability and increasing costs associated with mining inputs and labour; the speculative nature of mineral exploration and development; title to properties; and the additional risks described in the Company's Annual Information Form for the year ended December 31, 2025 filed with the Canadian securities regulatory authorities under the Company's SEDAR+ profile at www.sedarplus.ca, and in the Company's Annual Report on Form 40-F filed with the SEC on EDGAR.

First Mining cautions that the foregoing list of factors that may affect future results is not exhaustive. When relying on our forward-looking statements to make decisions with respect to First Mining, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. First Mining does not undertake to update any forward-looking statement, whether written or oral, that may be made from time to time by the Company or on our behalf, except as required by law.

Cautionary Note to United States Investors

The Company is a "foreign private issuer" as defined in Rule 3b-4 under the United States Securities Exchange Act of 1934, as amended, and is eligible to rely upon the Canada-U.S. Multi-Jurisdictional Disclosure System, and is therefore permitted to prepare the technical information contained herein in accordance with the requirements of the securities laws in effect in Canada, which differ from the requirements of the securities laws currently in effect in the United States. Accordingly, information concerning mineral deposits set forth herein may not be comparable with information made public by companies that report in accordance with U.S. standards.

Technical disclosure contained in this news release has not been prepared in accordance with the requirements of United States securities laws and uses terms that comply with reporting standards in Canada with certain estimates prepared in accordance with NI 43-101.

NI 43-101 is a rule developed by the Canadian Securities Administrators that establishes standards for all public disclosure an issuer makes of scientific and technical information concerning the issuer's material mineral projects.

SOURCE First Mining Gold Corp.

Share this article

New division provides purpose-built HVAC installations, maintenance, and 24/7 emergency service exclusively for steel mills and metal related industrial facilities

LITTLE ROCK, Ark., Sept. 14, 2026 /PRNewswire/ -- The Systems Group (TSG), a family-owned group of companies serving the steel industry since 1970, today announced the launch of Systems Cool Air Solutions, a new division dedicated to providing industrial HVAC services exclusively for steel mills and metal related industrial facilities.

Systems Cool Air Solutions will offer comprehensive HVAC capabilities including new installations, preventive maintenance programs, and 24/7 emergency response — all designed specifically for the extreme demands of steel mill environments. The division will be led by Ted Smith as General Manager and Kyle Elkins as Sales Director.

Smith brings more than 30 years of industrial HVAC leadership to the role, having served as Chief Operating Officer at multiple leading industrial HVAC companies. During his tenure, he oversaw HVAC operations, field teams, and project execution for steel mills and heavy industrial facilities across the Southeast. Elkins, a University of Arkansas graduate, joins as Sales Director after building a track record in business development and contract negotiation in the industrial HVAC space. Together, they bring deep expertise in the unique challenges of keeping steel mill environments climate-controlled.

The new division marks TSG's eighth operating company and further expands the organization's ability to serve as a single-source partner for steel producers. Cool Air Solutions joins TSG's existing divisions — Spray-Cooled, Plant Services, Clean Air (Industrial Air Filtration), Refractory Solutions, Contracting, Fab & Machine, and Engineering — to provide the most comprehensive suite of steel mill services under one roof.

"Why HVAC? We kept hearing the same thing from our customers — finding an HVAC contractor who truly understands their environment is harder than it should be. Cool Air Solutions changes that. We're not a commercial HVAC company that occasionally takes an industrial job. Steel mills are all we do."

— Kyle Morgan, President, The Systems Group

Cool Air Solutions' service offerings include control room and motor control center (MCC) climate systems, offices, overhead crane cab HVAC and pressurization, custom ductwork and sheet metal fabrication, ventilation and exhaust systems, building automation and controls, and industrial refrigeration systems. The division will also offer comprehensive preventive maintenance programs designed to maximize equipment uptime in harsh industrial conditions.

The launch creates significant cross-division synergies within the TSG family of companies. Clean Air's SMAC (Self-Maintaining Air Cleaner) industrial filtration projects pair naturally with HVAC work in the same mill environment.

"Every TSG division was built to serve the steel industry, and Cool Air Solutions is the natural next step. When you combine HVAC with our air filtration, refractory, maintenance, fabrication, and construction capabilities, you get a partner that can handle virtually every service need in a steel mill — under one master service agreement."

— Lee Morgan, CEO, The Systems Group

Systems Cool Air Solutions will operate from TSG's regional office in Blytheville, AR, with the ability to deploy service teams to steel mill facilities nationwide.

About The Systems Group

The Systems Group is a family-owned group of companies 100% focused on servicing the steel industry with engineered solutions designed for a safer, more productive steel industry. Founded in 1970 by Charles Hays, Sr., TSG has grown to approximately 1,000 employees across multiple divisions serving steel producers throughout the United States and Spray-Cooled™ equipment in 100+ steel mills across 22 countries. TSG is ranked #227 on ENR's 2025 Top 600 Specialty Contractors List. For more information on TSG, visit https://www.tsg.bz; for information on Cool Air Solutions, visit https://hvac.tsg.bz.

SOURCE Systems Cool Air Solutions

Share this article

WOOSTER, Ohio, Sept. 14, 2026 /PRNewswire/ -- PRC-Saltillo, a pioneer and global leader in augmentative and alternative communication (AAC), announces the global launch of the Genesis product line, a new generation of communication devices designed to expand communication possibilities for adults, teens, and children with acquired or long-term complex communication needs, including ALS and cerebral palsy.

The Genesis product line debuts with two highly customizable Windows®-based AAC solutions: the 13-inch Genesis 13 and the 16-inch Genesis 16. Backed by 60 years of engineering, clinical, linguistic, and communicator expertise, Genesis is designed to help communicators make the most of every opportunity with thoughtful design, access flexibility, and familiar tools that support everyday communication.

"Innovation is meaningful when it helps people connect more fully with the world around them," said Sarah Wilds, CEO. "Genesis brings together thoughtful design, state of the art durability, and personalization to open new possibilities for communicators across the global AAC community."

Designed around real-world communication needs

Genesis 13 and Genesis 16 include features designed to support independence, clarity, connection, and comfort across everyday environments.  The new devices offer expansive, vibrant screens, a three-inch angled partner display, customizable quick access controls, surround-style audio from front- and rear-facing speakers, a multi-angle kickstand, larger power and volume buttons, long-lasting battery life, and generous storage capacity.

Flexible access and personalization

Genesis solutions can be customized to fit each communicator's body, access method, routines, and style. Access options include an advanced eye tracker with improved outdoor performance, a head tracker, wireless and wired switches with two switch-scanning ports, TouchGuides, and keyguards. Communicators can also personalize their device with an all-black design, ten frame colors, a cushioned backpack, and heavy-duty mount options.

Familiar tools, trusted support

Genesis makes the transition to a new device feel familiar with many of the features and tools PRC-Saltillo customers already use and trust. Every Genesis device supports robust vocabulary options, including Unity®/Unidad®, LAMP Words for Life®, Essence®, WordPower®, CoreScanner™, and more, along with a Windows-based platform and Empower® and/or NuVoice® software for familiar navigation and a seamless transition.

Every Genesis device also includes PRC-Saltillo support for communicators and communication partners. Genesis devices are protected by the High Five Warranty, offering five years of coverage to help keep communicators communicating at their highest level.

Join the Global New Possibilities Tour

To celebrate the global launch of Genesis, PRC-Saltillo is taking the New Possibilities Tour around the world, giving communicators, families, and professionals the opportunity to explore Genesis firsthand and discover what the new devices can do.

Genesis trial and purchased devices will start shipping in the U.S. in October. PRC-Saltillo AAC Consultants are available to share Genesis product information, answer insurance funding questions, and support customers as they begin something extraordinary. Customers outside the U.S. may contact their local PRC-Saltillo subsidiary to learn more about Genesis options in their region.

About PRC-Saltillo

Founded in 1966, PRC-Saltillo is a pioneer and global leader in augmentative and alternative communication (AAC) technology for individuals with complex communication needs. The company offers a full range of speech-generating devices, industry-leading AAC apps, and research-based vocabulary systems. PRC-Saltillo is 100% employee-owned and headquartered in Wooster, Ohio, with subsidiaries in the United Kingdom, Australia, Canada, Germany, Singapore, and India.

SOURCE PRC-Saltillo

Share this article

Direct metallization process to produce 5.9 metric tons of nuclear fuel per unit per year

WEST VALLEY CITY, Utah, Sept. 14, 2026 /PRNewswire/ -- Nusano, a physics company pioneering advances in radioisotope and nuclear fuel production, has been selected by the National Reactor Innovation Center (NRIC) and the U.S. Department of Energy to develop its direct metallization HALEU nuclear fuel production line, as part of the Nuclear Energy Launch Pad Program, a federal initiative designed to accelerate innovative nuclear technologies from concept to commercial deployment.

Through Launch Pad, Nusano will gain access to DOE authorization processes, national laboratory expertise, infrastructure, technical resources, and project support intended to accelerate advanced nuclear technologies from development to deployment.

The Nusano HALEU production line uses metallic uranium feedstock instead of fluorinated uranium gas. The system is designed to produce HALEU in a single enrichment pass while reducing cost, enabling modular scalability, and eliminating hazardous fluorine chemistry. A Nusano HALEU unit requires just 1,200 square feet of operating space, allowing for additional units to be deployed incrementally as market demand grows. Nusano expects each unit will produce 5.9 metric tons (MT) of HALEU per year, with the first unit scheduled to be operational in 2031.

"Selection for Launch Pad signals Nusano's HALEU technology and team are ready to move forward," said Keith Titus, CEO of Nusano. "The review process considered each project's technical merit, operational readiness, and alignment with national strategic priorities. We're proud to be included and grateful for the opportunity to advance work to support America's energy independence."

Why HALEU Matters

HALEU, or high-assay low-enriched uranium, contains more uranium-235 than the fuel used in most reactors today while remaining below the threshold for highly enriched uranium. This makes HALEU useful for many small modular reactors, which can use it to produce more power from less fuel, run longer between refueling, and fit into smaller, more flexible designs.

Interest in SMRs is growing because they promise reliable, secure and affordable power in a more flexible and scalable format than traditional large nuclear plants. For many advanced designs, deployment depends on reliable access to HALEU fuel, making domestic fuel availability a critical factor in whether the market can scale.

The United States Department of Energy (DOE) estimates that domestic demand for HALEU could reach 50 MTU per year by 2035. Today, less than 1 MTU of HALEU is produced in the U.S. annually.

The Direct Metallization Difference

Currently, enriched uranium is primarily produced using gas centrifuges. This process spins uranium hexafluoride gas at high speed through connected centrifuges to increase the concentration of uranium-235.

Nusano's direct-metal feedstock pathway moves metallurgy earlier in the enrichment process and eliminates hazardous fluorine chemistry. The uranium feedstock is converted to metal before enrichment, then Nusano applies proprietary separation techniques to separate atoms by mass. For HALEU, the platform takes in uranium metal, enriches and separates uranium-235 from uranium-238, and outputs HALEU in metallic product form.

Benefits of direct metallization include:

- Simplicity – Eliminates the UF₆ conversion, deconversion, and metallization required in a gas centrifuge production process.

- Speed – Achieves full enrichment, from natural uranium to 19.75% enriched material, in a single-pass enrichment process.

- Efficiency – High feed-to-product ratio delivers high-volume HALEU production.

To learn more about Nusano's direct metallization HALEU platform, visit nusano.com/haleu.

About Nusano

Headquartered in West Valley City, Utah, Nusano is a privately held physics company working to stabilize supply chains, advance American national security by reducing dependency on foreign supply, and enable once-in-a-generation innovations in fields ranging from healthcare to nuclear energy. The company is commercializing platform technologies for radioisotope production, stable isotope enrichment, and advanced separation techniques. Together, these proprietary systems and methods are poised to supply the fight against cancer and help fuel America's nuclear renaissance. For more, visit nusano.com.

Contact:

Scott Larrivee, Nusano, (608) 345-6629, [email protected]

SOURCE Nusano

Share this article

SMArtX is a managed account technology and TAMP platform for multiple RIAs, broker-dealers, asset managers, custodians, and FinTech firms. Learn more at www.smartxadvisory.com

NEW YORK, Sept. 14, 2026 /PRNewswire/ -- Infrastructure Capital Advisors, LLC (Infrastructure Capital), a leading provider of investment management solutions designed to meet the needs of income-focused investors, is excited to offer its strategies to SMArtX Advisory Solutions.

"In the current market environment, investors are seeking high income with low volatility," said Jay Hatfield, CEO and CIO of Infrastructure Capital Advisors. "Our active income strategies are constructed to offer investors the benefits of high yielding diversified baskets of fixed and equity income, with rigorous and active risk management." Infrastructure Capital manages over $4 billion in assets as of 09/8/2026 and delivers income-focused investment solutions to its clients.

The Virtus InfraCap U.S. Preferred Stock ETF (NYSE Arca: PFFA), InfraCap REIT Preferred ETF (NYSE Arca: PFFR), InfraCap MLP ETF (NYSE Arca: AMZA), Infrastructure Capital Equity Income ETF (NYSE Arca: ICAP), Infrastructure Capital Small Cap Income ETF (NYSE Arca: SCAP), and Infrastructure Capital Bond Income ETF (NYSE Arca: BNDS) are strategies that are now available on the SMArtX Advisory Solutions platform.

About Infrastructure Capital Advisors

Infrastructure Capital Advisors, LLC (ICA) is an SEC-registered investment adviser that manages exchange traded funds (ETFs) and a series of private funds. The firm was formed in 2012 and is based in New York City. ICA seeks total-return opportunities driven by catalysts, largely in key infrastructure sectors. These sectors include energy, real estate, transportation, industrials and utilities. It often identifies opportunities in entities that are not taxed at the entity level, such as master limited partnerships ("MLPs") and real estate investment trusts ("REITs"). It also looks for opportunities in credit and related securities, such as preferred stocks.

Current income is a primary objective in most, but not all, of ICA's investing activities. Consequently, the focus is generally on companies that generate and distribute substantial streams of free cash flow. This approach is based on the belief that tangible assets that produce free cash flow have intrinsic values that are unlikely to deteriorate over time. For more information, please visit infracapfunds.com.

Income Investing with Infrastructure Capital

Jay D. Hatfield is the Chief Investment Officer for all of the Infrastructure Capital funds and brings more than 30 years of experience to his work on behalf of clients. As of the date of this release, Infrastructure Capital manages over $4B in total assets.

BNDS ETF strategy is to target high yield investments across fixed-income securities, predominately focusing on corporate bonds. Infrastructure Capital seeks positive security selection versus the benchmark by using a mix of quantitative and qualitative analysis with an emphasis on fixed-income securities that are believed to be undervalued when considering factors such as term premium, credit premium, liquidity premium, industry, sector, and market capitalization.

SCAP ETF seeks total return through a blended approach of capital appreciation and current income. The Fund focuses primarily on the securities of U.S.-listed small cap companies, which is defined as companies with a market capitalization within the range of companies in the Russell 2000 Index. Investments may take the form of common stocks, preferred stocks, convertible securities, debt instruments, equity-linked notes, or other small cap-focused ETFs.

ICAP ETF will primarily invest in equity securities of companies with a strong track record of paying dividends during normal market conditions. The Fund's portfolio of equities will generally be a diversified selection of securities, including a broad cross-section of sectors and sub-sectors, such as REITs, Utilities, Industrials, pipelines, and financials.

Infrastructure Capital ETF lineup includes the Virtus InfraCap U.S. Preferred Stock ETF (NYSE Arca: PFFA), InfraCap REIT Preferred ETF (NYSE Arca: PFFR), InfraCap MLP ETF (NYSE Arca: AMZA), the InfraCap Equity Income Fund ETF (NYSE Arca: ICAP), and the Infrastructure Capital Bond Income ETF (NYSE Arca: BNDS), and Infrastructure Capital Small Cap Income ETF (NYSE Arca: SCAP).

Follow Infrastructure Capital on social media for all of the firm's need-to-know market commentary and economic outlook at:

Monthly Market and Economic Webinar - Jay Hatfield

Register for our monthly Market & Economic Insights webinar series. Can't join live each month? Register anyway and we will email you a playback video link.

DISCLOSURE

Opinions represented are subject to change and should not be considered investment advice. Past performance is not indicative of future results. This data was prepared using sources of information generally believed to be reliable; however, its accuracy is not guaranteed. The Russell 2000 Index is a small-cap U.S. stock market index that makes up the smallest 2,000 stocks in the Russell 3000 Index. It is not possible to invest directly in an index. The term premium is the extra return that investors demand for holding a long-term bond instead of a series of short-term bonds. A credit premium (often called a credit risk premium or default premium) is the excess return or additional yield an investor requires to hold a debt instrument issued by an entity other than a risk-free government. A liquidity premium is the extra return or higher yield that investors demand for holding an asset that cannot be quickly and easily converted into cash at its fair market value. Preferred stock is a unique class of corporate ownership that combines features of both stocks and bonds, giving investors priority over common stockholders for receiving fixed dividend payments and asset distributions. Convertible securities are hybrid financial instruments—usually bonds or preferred shares—that give investors the right to exchange the security for a predetermined number of shares of the issuing company's common stock. An Equity-Linked Note (ELN) is a debt instrument where the principal payment or interest payout is tied to the performance of an underlying equity, such as a single stock, a basket of stocks, or a market index (like the S&P 500). REITs, or real estate investment trusts, are companies that own or finance income-producing real estate across a range of property sectors.

Investors should consider the investment objectives, risks, charges, and expenses carefully before investing. For a prospectus with this and other information about the ETFs, please click here. Please read the prospectus carefully before investing. For more information about the Fund, Fund strategies or InfraCap, please reach out to Craig Starr at 212-763-8336 ([email protected]).

A word about QVOL Risk: Investing involves risk. Principal loss is possible. The Fund is a recently organized investment company with no operating history prior to the date of this Prospectus. As a result, prospective investors have no track record or history on which to base their investment decision. Derivatives may pose risks in addition to and greater than those associated with investing directly in securities, currencies or other investments, including risks relating to leverage, imperfect correlations with underlying investments or the Fund's other portfolio holdings, high price volatility, lack of availability, counterparty credit, liquidity, valuation and legal restrictions. Options transactions involve special risks that may make it difficult or impossible to close a position when the Fund desires. The prices of securities the Adviser believes are undervalued may not appreciate as anticipated or may go down, the valuations may never improve or returns on value equity securities may be less than returns on other styles of investing or the overall stock market. Leverage is investment exposure which exceeds the initial amount invested. When the Fund borrows money for investment purposes, or when the Fund engages in certain derivative transactions, such as options, the Fund may become leveraged. A high portfolio turnover rate (portfolio turnover in excess of 100% of the average value of the Fund's portfolio) has the potential to result in the realization and distribution to shareholders of higher capital gains, which may subject you to a higher tax liability.

Please see prospectus for discussion of risks. QVOL fund distributor, Quasar Distributors, LLC.

A word about SCAP risk: Investing involves risk, including possible loss of principal. An investment in the Fund may be subject to risks which include, among others, investing in equities securities, dividend paying securities, utilities, small-, mid- and large-capitalization companies, real estate investment trusts, master limited partnerships, foreign investments and emerging, debt securities, depositary receipts, market events, operational, high portfolio turnover, trading issues, active management, fund shares trading, premium/discount risk and liquidity of fund shares, which may make these investments volatile in price. Foreign investments are subject to risks, which include changes in economic and political conditions, foreign currency fluctuations, changes in foreign regulations, and changes in currency exchange rates which may negatively impact the Fund's returns. Small and Medium-capitalization companies, foreign investments and high yielding equity and debt securities may be subject to elevated risks. The Fund is a recently organized investment company with no operating history. Please see prospectus for discussion of risks. Diversification cannot assure a profit or protect against loss in a down market. SCAP is distributed by Quasar Distributors, LLC.

NEW YORK, Sept. 14, 2026 /PRNewswire/ -- Galaxy Digital Inc. (Nasdaq: GLXY) ("Galaxy" or "the Company") today announced that Taylor Reinhardt has joined the Company as Head of Investor Relations. She will report to Chief Financial Officer Tony Paquette.

"As Galaxy has grown into a company spanning digital assets and AI infrastructure, the market's understanding of that story needs to keep pace," said Tony Paquette, Chief Financial Officer of Galaxy. "Taylor has spent her career helping sophisticated investors make sense of complex, fast-evolving businesses, which is exactly the skill set we need as Galaxy enters its next phase of growth. She'll play a key role in how we engage with our shareholders and the broader investment community."

Prior to joining Galaxy, Ms. Reinhardt served as Head of Investor Relations, Marketing and Communications at Perella Weinberg, joining in 2021 in conjunction with the firm's public listing on the Nasdaq. Before that, she spent six years in Investor Relations and Corporate Communications at Apollo Global Management, and began her career in Investor Relations and Corporate Communications at Teneo Holdings.

"Galaxy is at such an exciting and pivotal moment in its trajectory, and I'm thrilled to be joining the Company as it continues to build across digital assets and AI infrastructure," said Ms. Reinhardt. "The breadth of the business, the pace of innovation, and the opportunity ahead make this an incredibly compelling story. I look forward to working with Tony and the broader team to engage with the investment community as Galaxy continues to execute on its ambitious vision."

Ms. Reinhardt succeeds Jonathan Goldowsky, who has transitioned to Co-Head of Europe at Galaxy.

About Galaxy

Galaxy Digital Inc. (Nasdaq: GLXY) is a global leader in digital assets and data center infrastructure, growing the economy that runs on code. Galaxy delivers the onchain infrastructure that connects institutions to digital assets, including trading, advisory, asset management, staking, self-custody, and tokenization. Galaxy also develops and operates data center infrastructure to power AI and HPC workloads. Anchored by its Helios campus in Texas, Galaxy is building a multi-gigawatt pipeline of more than 5.7 GW of potential capacity, positioning it among the largest and fastest-growing data center developers in North America. The Company is headquartered in New York City, with offices across North America, Europe, the Middle East, and Asia. Additional information about Galaxy's businesses and products is available on www.galaxy.com.

SOURCE Galaxy Digital Inc.

Share this article